6 các kết quả
BACKGROUND OF THE INVENTION
This invention relates to regimens of administering compounds, which are antagonists of the progesterone receptor in combination with a progestin, an estrogen, or both. Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand
FIELD OF THE INVENTION
This invention relates to regimens of administering compounds which are antagonists of the progesterone receptor in combination with a progestin, an estrogen, or both.
BACKGROUND OF THE INVENTION
Intracellular receptors (IR) form a class of structurally related gene regulators
FIELD OF THE INVENTION
This invention relates to regimens of administering compounds which are antagonists of the progesterone receptor in combination with a progestin, an estrogen, or both.
BACKGROUND OF THE INVENTION
Intracellular receptors (IR) form a class of structurally related gene regulators
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to a new class of compounds to wit: to 2-(hydroxy-2-alkylphenylamino)-oxazolines and to 2-(hydroxy-2-alkylphenylamino)-thiazolines which are active as agents for reducing or maintaining intraocular pressure, and
BACKGROUND OF THE INVENTION
This invention relates to regimens of administering compounds which are antagonists of the progesterone receptor.
Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R. M. Evans, Science,
FIELD OF THE INVENTION
This invention relates to regimens of administering compounds which are antagonists of the progesterone receptor.
BACKGROUND OF THE INVENTION
Intracellular receptors (IR) form a class of structurally related gene regulators known as "ligand dependent transcription factors" (R.